Guilford Gliadel in initial surgery
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Guilford's Gliadel (polifeprosan 20 with carmustine implant) gains approval Feb. 25 for newly diagnosed, high-grade malignant glioma patients as an adjunct to surgery and radiation. Approval is based on a double-blind, placebo-controlled trial in 240 patients with a follow-up period of up to 48 months. Nine of the 11 surviving patients at the last follow-up received Gliadel. Median survival with Gliadel increased to 13.9 months from 11.6 months (p<0.05); the firm says marketing for the indication will highlight survival benefit. Guilford previously estimated market penetration of 33% in the recurrent setting, but only 8% in the initial surgery market. The firm aims to increase market share in the initial surgery group to the low teens in 200
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.